Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

B2B

Financiado

Cerrado

Modeling spontaneous Breast cancer metastasis TO the Bone with a first of its ki...

Modeling spontaneous Breast cancer metastasis TO the Bone with a first of its kind 3D device that recapitulates physiological tissue level complexity. Cancer patients developing a metastatic disease are considered incurable. Breast cancer hits 1 woman in 8, and its most common metastatic site is the bone. A major hurdle to overcome breast cancer mortality is the lack of understa... ver más

31/12/2022

CNR

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

CONSIGLIO NAZIONALE DELLE RICERCHE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 10 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-12-31

FETOPEN-01-2016-2017: FET-Open research and innovation ac...

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

10 Participantes

CNR

711.89K€ | Lider

ETH Zürich

45.00K€ | Participante

Start Codon Limited

234.24K€ | Participante

ERASMUS MC

390.83K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ICE-METs Interstitium on a chip to explore its role in cancer metasta... 213K€ Cerrado

BEACONSANDEGG Mechanobiology of cancer progression 2M€ Cerrado

MiTuMi Bioengineered Matrices Mimicking the Lung Tumor Microenviron... 145K€ Cerrado

3DCanPredict Predicting clinical response to anticancer drugs using 3D bi... 150K€ Cerrado

VASTO VAScularised Tumour Organoids on a chip with human placenta... 150K€ Cerrado

DPI2015-64221-C2-1-R DISEÑO Y FABRICACION DE DISPOSITIVOS MICROFLUIDICOS PARA EL... 197K€ Cerrado

Duración del proyecto: 55 meses Fecha Inicio: 2018-05-25
Fecha Fin: 2022-12-31

Líder del proyecto

CONSIGLIO NAZIONALE DELLE RICERCHE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer patients developing a metastatic disease are considered incurable. Breast cancer hits 1 woman in 8, and its most common metastatic site is the bone. A major hurdle to overcome breast cancer mortality is the lack of understanding of dynamics leading to the spread of breast cancer cells to the bone. Consequently, metastasis-suppressing agents have not been found to date, neither as newly developed drugs nor as repurposing of existing ones. The aim of the B2B device is to generate a first-of-a-kind 3D model of spontaneous breast cancer metastasis to the bone to dissect the complexity of the metastatic process and empower high-throughput drug screening in a physiological context. B2B will pursue its goal of developing a novel hybrid device able to 1) propagate patient-derived tumor organoids of clinically-relevant dimensions, with their own self-assembled micro-capillary networks, which are 2) continuously linked to a 3D bioprinted macro-vascular tree, organized in a hierarchical branched structure, connected in a closed circuit with 3) a vascularized marrow-containing bone ossicle, as the metastatic target. This is a unique approach, spanning the micro (single circulating metastatic cells, passing the endothelial barrier of capillary networks) to macro (tumor organoids and ossicles of clinically relevant size and tissue composition, connected by a hierarchically organized vascular tree) continuum to recapitulate spontaneous bone metastasis formation in breast cancer. This technology will transcend the limitations of current in vitro technologies, enabling physiological tissue-level complexity with organoids comprising several million cells, and its expected impact will be three-fold: to recapitulate the spontaneous metastatic process in breast cancer, to provide a breakthrough technology to investigate metastasis longitudinally and at the single cell level, and to lead to the identification of metastasis-suppressing therapies for breast cancer patients.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores